Picture of CureVac NV logo

5CV CureVac NV News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

UK Stocks-Factors to watch on July 3 (updated)

(Adds new items, updates futures)
       July 3 (Reuters) - Britain's FTSE 100  .FTSE  index is
seen opening higher on Wednesday, with futures  FFIc1  up 0.7%.
    
    * GSK: GSK  GSK.L  has bought from CureVac  5CV.DE ,
 CVAC.O  the full rights to develop and manufacture vaccine
candidates for influenza and COVID-19 that use messenger RNA
(mRNA) technology for up to 1.05 billion euros ($1.13 billion),
it said.
    * VODAFONE: Britain's Vodafone  VOD.L  and Virgin Media O2
agreed a new network sharing agreement to extend their existing
tie-up for more than a decade, in a deal they said was subject
to approval of the merger between Vodafone and Three UK.
    * KEYWORDS STUDIOS: Private equity firm EQT  EQTAB.ST  will
buy UK-based video game services group Keywords Studios  KWS.L 
in a 2.2 billion pound deal, the companies said.
    * TOPPS TILES: British tile retailer Topps Tiles  TPT.L 
said that challenging market conditions had persisted into the
second half of the fiscal year amid weakness in the home repair
and sales segments.
    * OIL: Oil prices rose after industry data showed a
bigger-than-expected draw in U.S. crude stockpiles, while the
market kept tabs on flaring tensions in the Middle East.
    * GOLD: Gold prices were flat as investors awaited minutes
of the Federal Reserve's last policy meeting for fresh cues on
when the U.S. central bank will start cutting interest rates.
    * METALS: Copper prices climbed with renewed hopes of U.S.
rate cuts, while dismal physical demand outlook from top
consumer China capped gains.

        
  
    * For more on the factors affecting European stocks, please
click on:  LIVE/     
    TODAY'S UK PAPERS
    > Financial Times                       PRESS/FT 
    > Other business headlines              PRESS/GB 


($1 = 0.9314 euros)

 (Reporting by Prerna Bedi and DhanushVignesh Babu in Bengaluru)
 ((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))

Recent news on CureVac NV

See all news